Insulet Co. (NASDAQ:PODD) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. grew its holdings in shares of Insulet Co. (NASDAQ:PODD) by 22.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,114 shares of the medical instruments supplier’s stock after buying an additional 2,736 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Insulet were worth $3,946,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new stake in Insulet during the 4th quarter worth $36,000. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 56 shares during the period. Friedenthal Financial purchased a new stake in shares of Insulet during the 4th quarter valued at about $57,000. Finally, TD Private Client Wealth LLC raised its holdings in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the period.

Insulet Price Performance

Shares of NASDAQ PODD opened at $248.38 on Thursday. The business has a 50 day simple moving average of $273.00 and a 200-day simple moving average of $254.08. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The company has a market capitalization of $17.44 billion, a price-to-earnings ratio of 42.90, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. As a group, equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PODD. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Wells Fargo & Company upped their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $292.06.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.